Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Authors:
- Rita NandaRNRita Nanda
- Laura Q.M. ChowLCLaura Q.M. Chow
- E. Claire DeesEDE. Claire Dees
- Raanan BergerRBRaanan Berger
- Shilpa GuptaSGShilpa Gupta
- Ravit GevaRGRavit Geva
- Lajos PusztaiLPLajos Pusztai
- Kumudu PathirajaKPKumudu Pathiraja
- Gursel AktanGAGursel Aktan
- Jonathan D. ChengJCJonathan D. Cheng
- Vassiliki KarantzaVKVassiliki Karantza
- Laurence BuisseretLBLaurence Buisseret
Top Cited Papers
- 20 July 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (21) , 2460-2467
Abstract
Purpose: Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC. Methods: KEYNOTE-012 ( ClinicalTrials.gov identifier: NCT01848834) was a multicenter, nonrandomized phase Ib trial of single-agent pembrolizumab given intravenously at 10 mg/kg every 2 weeks to patients with advanced PD-L1–positive (expression in stroma or ≥ 1% of tumor cells by immunohistochemistry) TNBC, gastric cancer, urothelial cancer, and head and neck cancer. This report focuses on the TNBC cohort. Results: Among 111 patients with TNBC whose tumor samples were screened for PD-L1 expression, 58.6% had PD-L1–positive tumors. Thirty-two women (median age, 50.5 years; range, 29 to 72 years) were enrolled and assessed for safety and antitumor activity. The median number of doses administered was five (range, 1 to 36 doses). Common toxicities were mild and similar to those observed in other tumor cohorts (eg, arthralgia, fatigue, myalgia, and nausea), and included five (15.6%) patients with grade ≥ 3 toxicity and one treatment-related death. Among the 27 patients who were evaluable for antitumor activity, the overall response rate was 18.5%, the median time to response was 17.9 weeks (range, 7.3 to 32.4 weeks), and the median duration of response was not yet reached (range, 15.0 to ≥ 47.3 weeks). Conclusion: This phase Ib study describes preliminary evidence of clinical activity and a potentially acceptable safety profile of pembrolizumab given every 2 weeks to patients with heavily pretreated, advanced TNBC. A single-agent phase II study examining a 200-mg dose given once every 3 weeks ( ClinicalTrials.gov identifier: NCT02447003) is ongoing.Keywords
This publication has 38 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal SubtypesClinical Cancer Research, 2009
- Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular SubtypesClinical Cancer Research, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast CarcinomaCancer Research, 2005